Article
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.
Breast cancer research and treatment - 1 Feb 2023
Xu Binghe, Sun Tao, Shi Yanxia, Cui Jiuwei, Yin Yongmei, Ouyang Quchang, Liu Qiang, Zhang Qingyuan, Chen Yiding, Wang Shouman, Wang Xiaojia, Tong Zhongsheng, Zhong Yahua, Wang Jiayu, Yan Min, Yan Xi, Wang Chuan, Feng Jifeng, Wang Xiuli, Hu Gang, Cheng Ying, Ge Ruimin, Zhu Zhaoyin, Zhang Wa, Shao Zhimin
Abstract excerpt
PURPOSE: To evaluate the efficacy and safety of pamiparib in patients with locally advanced or metastatic human epidermal growth factor receptor 2-negative (HER2-) breast cancer, with deleterious or suspected deleterious germline BRCA1/2 mutations (gBRCA1/2 m). METHODS: In this open-label, phase II, multicenter study in China (NCT03575065), patients with triple-negative breast cancer (TNBC cohort) or hormone...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.